Abstract
The hematological module of the Athlete Biological Passport (ABP) is used in elite sport for antidoping purposes. Its aim is to better target athletes for testing and to indirectly detect blood doping. The ABP allows to monitor hematological variations in athletes using selected primary blood biomarkers (hemoglobin concentration ([Hb] and reticulocyte percentage (Ret%)) with an adaptive Bayesian model to set individual upper and lower limits. If values fall without the individual limits, an athlete may be further targeted and ultimately sanctioned.
Since [Hb] and Ret% vary with plasma volume (PV) fluctuations, possibly caused by training load changes, we investigated the putative influence of acute and chronic training load changes on the ABP variables.
Monthly blood samples were collected over one year in 10 elite cyclists (25.6 ± 3.4 yrs, 181 ± 4 cm, 71.3 ± 4.9 kg, 6.7 ± 0.8 W.kg-1 5-min maximal power output) to calculate individual ABP profiles and monitor hematological variables. Total hemoglobin mass (Hbmass) and PV were additionally measured by carbon monoxide rebreathing. Acute and chronic training loads – respectively 5 and 42 days before sampling – were calculated considering duration and intensity (training stress score, TSS™).
[Hb] averaged 14.2 ± 0.0 (mean ± SD) g.dL-1 (range: 13.3 to 15.5 g·dl-1) over the study with significant changes over time (P = 0.004). Hbmass was 1’030 ± 87 g (range: 842 to 1116 g) with no significant variations over time (P = 0.118), whereas PV was 4309 ± 350 mL (range: 3688 to 4751 mL) with a time-effect observed over the study time (P = 0.014). Higher acute – but not chronic – training loads were associated with significantly decreased [Hb] (P <0.001). Although individual hematological variations were observed, all ABP variables remained within the individually calculated limits.
Our results support that acute training load variations significantly affect [Hb], likely due to short-term PV fluctuations, underlining the importance of considering training load when interpreting individual ABP variations for anti-doping purposes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by a grant from WADAs Science Department (ISF19D06RF)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the regional research ethics committee (CER-VD, Lausanne, Switzerland, #2018-01019) and conducted in respect of the Declaration of Helsinki
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript may be requested to the corresponding author.
